BPC-157 and TB-500 are listed together by all four vendors we review, and three of the four sell a blend of both. We went looking for what backs the pairing: the published studies, the FDA and anti-doping record, and what the vendors show. This is not advice to use anything, and the vendors label these products for laboratory research only.
What each compound is
BPC-157 is a 15 amino acid peptide that a 2025 systematic review calls a naturally occurring gastric peptide. TB-500 is, in the FDA's own table, the thymosin beta-4 fragment LKKTETQ, a seven amino acid piece of the larger protein . Vendors sell both separately and blended, under names such as BB10, KLOW and Wolverine.
What has been published
A 2025 systematic review in HSS Journal (Vasireddi et al.) searched PubMed, Cochrane and Embase through 3 June 2024. It found 544 articles, included 36, and counted 35 preclinical studies and one clinical study. The animal work covers muscle, tendon, ligament and bone injury. The review says BPC-157 lacks FDA approval and is banned in professional sports, and that it found no clinical safety data. We found no equivalent review for TB-500 and no human trial of TB-500 on its own.
The one clinical study is a 2021 retrospective chart review from a clinic in Orlando, Florida (Lee and Padgett). Of 17 patients who had a peptide injected into the knee joint, 16 were reached by phone. Twelve had received BPC-157 alone and four had received it with thymosin beta-4. Patients rated their own pain, and the authors say no specific tool measured function, quality of life, stiffness or daily activities. The paper reports relief in 11 of the 12 BPC-157-only patients and in 14 of 16 overall (87.5%). The systematic review summarizes the same study differently: 7 of 12 patients reported relief for more than six months. The abstract describes no comparison group and does not say where the peptide came from, so it says nothing about a vendor's vial.
Regulatory and anti-doping status
Both names sit in the FDA's table of bulk drug substances that were nominated for compounding and then withdrawn by their nominators, on a page current as of 22 April 2026 . For BPC-157 the table says the agency "has identified no, or only limited, safety-related information for the proposed routes of administration." For the TB-500 fragment it says the agency "has not identified any human exposure data" for drug products containing it.
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee took up both substances for possible inclusion on the 503A bulks list: BPC-157 for ulcerative colitis and TB-500 for wound healing, according to the FDA's meeting page . ABC News reported on 24 July that the committee voted narrowly to recommend adding both, with four other peptides, against the unanimous opposition of FDA staff scientists. The vote is non-binding, and we found no final FDA decision in the sources we searched.
USADA says BPC-157 is prohibited under the S0 category of non-approved substances on the WADA Prohibited List . The Cologne anti-doping laboratory's copy of the 2026 S2 section, which it describes as prohibited at all times in and out of competition, names "Thymosin-ß4 and its derivatives, e.g., TB-500" . Tested athletes should read the current list themselves.
What the vendors list
Swipe the table sideways to see every column.
| Vendor | BPC-157 | TB-500 | Blend of both |
|---|---|---|---|
| Peptryn | 5mg and 10mg. Lot 2026-08-05 reads 99.50% by HPLC-UV-MS, endotoxin negative, tested by MZ Biolabs. | 10mg, $89.99. Lot 2026-08-05 reads 99.84%, endotoxin negative, MZ Biolabs. | Wolverine blend, 20mg, $200.00. Lot 2026-08-05 reads 99.13%. |
| American Peptides | 5mg $60, 10mg $80, 15mg $100. Its COA library lists lots BP5-0803, BP10-0803 and BP15-0803. | 10mg, $100. Its library lists lot TB10-0803. | A 20mg blend at $195 and a three-vial bundle. |
| Core Power Peptides | 10mg at $99.99, plus capsules, two sprays, and acetate and arginine versions. | Fragment 17-23 10mg at $94.99 (out of stock), plus thymosin beta-4 and acetate listings. | Three blends, including BB10 (BPC-157 5mg and TB-500 5mg) at $129.00, BBG70 and KLOW 80. |
| Peptides for Sale | 6mg and 10mg, $61.99 to $99.00, plus capsules, sprays, and acetate and arginine versions. | TB500 acetate, $70.00. | None found. |
Peptryn states a lot, a purity figure, an endotoxin result and a lab for all three of its listings. The Core Power Peptides BPC-157 10mg page has a COA tab and gives no lab, lot or test result, though its headline says 99% purity. Peptides for Sale says a certificate of analysis is available and names no lab or lot. Our guide to reading a COA explains what each field should show.
What this means for a reader
No source above tests a vial bought from a research vendor, and none reports a muscle result. The only human data is a small, retrospective series of self-rated knee pain. Our posts on the best peptides for muscle growth and on what trials measured for muscle gain cover other compounds. Neither covers BPC-157 or TB-500, and this post found no muscle result for them either.
Frequently asked questions
Is there a human trial of BPC-157?
One clinical study. A 2021 retrospective chart review reached 16 patients with knee pain and reported self-rated relief, with no tool measuring function and no comparison group described. We found no human trial of TB-500 on its own.
Are BPC-157 and TB-500 approved by the FDA?
We found no approval for either. Both sit in an FDA table of compounding nominations withdrawn by their nominators. In July 2026 an FDA advisory committee narrowly recommended adding both to a compounding list, a non-binding vote. We found no final FDA decision.
Are they banned in sport?
Yes. USADA says BPC-157 is prohibited under the WADA Prohibited List's S0 category. The Cologne laboratory's copy of the 2026 S2 section lists thymosin-ß4 and its derivatives, including TB-500, as prohibited at all times. Tested athletes should check the current list.